Drug recall · February 10, 2021
Nortriptyline HCl Capsules recall
Why: CGMP deviations.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Nortriptyline HCl Capsules, USP equivalent to 10mg base Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532 NDC 51672-4001-1
- Lots / codes
AC05096, AC05098, and AC05099; Exp 10/31/2022
- Quantity
- 44,256 bottles
- Company
- Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY
- Distribution
- Nationwide
- Initiated
- January 8, 2021 · Voluntary: Firm initiated
- Classified
- February 1, 2021
- Reported
- February 10, 2021
- Ended
- September 7, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nortriptyline
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.